As Hong Kong-listed Chinese pharmaceutical enterprises approach full-year profitability through expanding drug sales and strategic global partnerships, the sector presents emerging opportunities for blockchain integration in supply chain and IP licensing. The revenue upturn positions these traditional healthcare companies as potential candidates for DeFi healthcare protocols and tokenized pharmaceutical assets.